X0708 D/A LIVE 0001682900 X-Vax Technology, Inc. 601 HERITAGE DRIVE, SUITE 138 JUPITER FL FLORIDA 33458 212-956-1111 DELAWARE None None Corporation true 2015 Ulf Wiinberg c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Executive Officer Chief Executive Officer (CEO) Andreas Eggert c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Executive Officer Chief Operating Officer (COO) Jacob Uittenbogaard c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Executive Officer Chief Financial Officer (CFO) Clare Kahn c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Executive Officer Chief Regulatory and Pre-Clinical Development Officer Richard Kenney c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Executive Officer Chief Development Officer Ian T. Clark c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Director Chairman of the Board of Directors Isaac Blech c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Director Vice Chairman of the Board of Directors Brian D. Finn c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Director William A. Haseltine c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Director Roger A. Jeffs c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Director Roger J. Pomerantz c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Director Robert R. Ruffolo c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Director Matthew R. Stober c/o X-Vax Technology, Inc. 601 Heritage Drive, Suite 138 Jupiter FL FLORIDA 33458 Director Biotechnology Decline to Disclose 06b true 0001213900-19-006609 2018-09-28 false true true false 20000 Maxim Group LLC 120708 None None 405 LEXINGTON AVENUE NEW YORK NY NEW YORK 10174 All States false 55000000 46682455 8317545 false 269 4668246 0 The placement agent was paid a fee of $362,567.50 relating to the conversion of certain convertible notes that were converted into the offering. 0 The company has agreed to pay its CEO and COO a bonus equal to their accrued/unpaid salary, half of which is due upon a closing of $15 million in the offering and half upon a closing of $30 million (or at the closing of a subsequent financing). false X-Vax Technology, Inc. /s/ Ulf Wiinberg Ulf Wiinberg Chief Executive Officer 2019-05-31